4.5 Review

Management of sickle cell disease from childhood through adulthood

期刊

BLOOD REVIEWS
卷 27, 期 6, 页码 279-287

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2013.09.001

关键词

Sickle cell disease; Haematology; Adult; Paediatric

资金

  1. Novartis Pharmaceuticals

向作者/读者索取更多资源

Sickle cell disease (SCD) is a genetic disorder characterised by anaemia and sickling of red blood cells, leading to chronic haemolytic anaemia, vascular injury, and organ dysfunction. Although children and adults experience many similar symptoms and problems, complications increase with age, leading to early mortality. Hydroxyurea (hydroxycarbamide), the only US Food and Drug Administration-approved treatment continues to be under-utilised and other treatments available to children are often inaccessible for adults. Haematopoietic stem-cell transplantation is a curative option, but is limited by a lack of donors and concerns for transplant-related toxicities. Although comprehensive programs exist in paediatrics, affected adults may not have access to preventative and comprehensive healthcare because of a lack of providers or care coordination. They are often forced to rely on urgent care, leading to increased healthcare utilisation costs and inappropriate treatment. This problem highlights the importance of primary care during the transition from paediatrics to adulthood. (C) 2013 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据